knee osteoarthritis
Conditions
Interventions
experimental group:Select ST35, EX-LE5, ST34, SP10, GB34, and ST36 as main points, and then select three matching points based on the patients meridian differentiation. The main points are treated wit
control group:Select ST35, EX-LE5, ST34, SP10, GB34, and ST36 as main points, and then select three matching points based on the patients meridian differentiation. The main points and the matching poi
Sponsors
Dongfang Hospital Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Meets the Western medical diagnostic criteria for knee osteoarthritis; (2) Aged between 40 and 75 years old (including 40 and 75 years old), regardless of gender; (3) Unilateral/bilateral knee joint pain, with a course of more than or equal to 6 months; (4) Radiological examination within 6 months showed KL staging as grades I-III; (5) NRS score >= 4 points in the past week; (6) All patients voluntarily participated in this clinical study and signed an informed consent form.
Exclusion criteria
Exclusion criteria: (1) Having a history of knee surgery or waiting for knee surgery (knee replacement or knee arthroscopic surgery); (2) Knee pain caused by other diseases (such as joint dissociation, severe joint effusion, infection, malignant tumors, autoimmune diseases, trauma, fractures, gout, lumbosacral diseases, etc.); (3) Evaluate a history of arthroscopy examination within 1 year and a history of intra-articular injection in the past 4 months for the joint; (4) Severe acute or chronic organic or psychiatric disorders; (5) Coagulation dysfunction diseases (such as hemophilia) or scar constitution; (6) The local skin of the affected knee has ulceration, allergies, or infections; (7) Allergy to needles, fear of puncturing or having a pacemaker. (8) Women preparing for pregnancy, pregnant and lactating women;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Numerical Rating Scale;Western Ontario and MCMaster Universities Osteoarthritis Index;The content of IL-1ß in human serum;Incidence rate of adverse events;The content of TNF-a in human serum; | — |
Secondary
| Measure | Time frame |
|---|---|
| 12-item short-form health survey, SF-12;Subjective overall efficacy evaluation of patients;Credibility/Expectation Evaluation; | — |
Countries
China
Contacts
Public ContactYuexin Li;Hua Li
Dongfang Hospital Beijing University of Chinese Medicine
Outcome results
None listed